No Improvement of Asthma Control Despite Changes in Pharmacological Treatment Patterns – 17 Years Follow Up
Authors:
- Caroline Ahlroth PindCPCaroline Ahlroth Pind
- Björn StällbergBSBjörn Ställberg
- Karin LisspersKLKarin Lisspers
- Josefin SundhJSJosefin Sundh
- Marta KisielMKMarta Kisiel
- Hanna SandelowskyHSHanna Sandelowsky
- Anna NagerANAnna Nager
- Mikael HasselgrenMHMikael Hasselgren
- Scott MontgomerySMScott Montgomery
- Maaike GiezemanMGMaaike Giezeman
- Gabriella EliasonGEGabriella Eliason
- Christer JansonChrister Janson
Open Access
- 1 December 2025
- journal article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 1825-1834
Abstract
Asthma control is reported to be low, often based on cross-sectional studies. There have been only a few longitudinal studies following asthma patients. We have assessed asthma control and asthma treatment over 17 years in a cohort of asthma patients. Patients, 18–75 years, with doctor-diagnosed asthma were randomly selected from healthcare units in Sweden. They answered questionnaires about symptoms and pharmacological treatment in 2005, 2012, and 2022. This study includes participants completing the last follow-up (n=437). Optimal asthma control was defined as no nocturnal asthma symptoms, use of short-acting β2-agonist twice or less in the past week, and no exacerbations in the last six months. There was no difference in frequency of optimal asthma control (41.8% vs 40.5%, p=0.68). Inhaled corticosteroids (ICS) in combination with long-acting β2-agonists increased from 2005 to 2022 as regular maintenance treatment (40.3% vs 46.7%, p=0.009) and as reliever medicine (11.6% vs 18.9%, p<0.001). The overall use of reliever medicine more than twice in the past week did not change (48.3% vs 51.6%, p=0.24). The overall use of ICS decreased (78.0% vs 70.4%, p<0.001), as did the occurrence of having a written action plan (21.9% vs 10.4%, p<0.001). Optimal asthma control and lack of written action plans were related to discontinuation of ICS treatment. Non-optimal asthma control is common long after diagnosis. Discontinuation of ICS may sometimes be due to optimal asthma control and no need for treatment, but lack of written action plans increases the risk of inappropriate discontinuation.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacological treatment of asthma in Sweden from 2005 to 2015Journal of Asthma, 2023
- Fatigue: A forgotten symptom of asthmaThe Clinical Respiratory Journal, 2021
- Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 studyThe Lancet Respiratory Medicine, 2021
- Factors associated with well‐controlled asthma—A cross‐sectional studyAllergy, 2019
- Controlled Trial of Budesonide–Formoterol as Needed for Mild AsthmaNew England Journal of Medicine, 2019
- A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma StudyRespiratory Medicine, 2016
- Adherence to inhaled corticosteroids by asthmatic patients: measurement and modelling.International Journal of Clinical Pharmacy, 2013
- Scheduled asthma management in general practice generally improve asthma control in those who attendRespiratory Medicine, 2012
- Asthma control in Europe: A real-world evaluation based on an international population-based studyJournal of Allergy and Clinical Immunology, 2007
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004